Lenalidomide Sandoz (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding triggers the degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic effects, modulation of cytokine release, enhanced immune cell activity, and direct anti‑tumor actions such as apoptosis and cell‑cycle arrest.

The specific dose and schedule of Lenalidomide Sandoz are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and other individual factors. Healthcare providers tailor the regimen to achieve optimal therapeutic benefit while minimizing risk.

Lenalidomide is classified as having an unknown pregnancy category and is considered potentially teratogenic. It should not be used by pregnant women, and effective contraception is required for both male and female patients of reproductive potential. Breastfeeding is not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lenalidomide belongs to the immunomodulatory class, offering a distinct mechanism compared with proteasome inhibitors or conventional chemotherapy. It provides oral administration, which can be more convenient, and has demonstrated efficacy in specific cytogenetic sub‑groups such as del(5q) myelodysplastic syndrome, often in combination with other agents.

Lenalidomide Sandoz should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light, and ensure the container is tightly closed when not in use.

The medication is taken orally, usually with or without food, as directed by the prescriber. Patients should swallow the tablet whole with a full glass of water and follow the dosing schedule provided by their healthcare professional.

Serious risks include venous thromboembolism, severe cutaneous reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, tumor lysis syndrome, and significant liver injury. Patients should be monitored closely for signs of these events, and any concerning symptoms should prompt immediate medical evaluation.

Lenalidomide Sandoz is contraindicated in patients with known hypersensitivity to lenalidomide or any of its excipients, in pregnant women, and in individuals who cannot adhere to strict contraception requirements. Clinicians should also avoid use in patients with uncontrolled infections or severe organ dysfunction where the risk outweighs benefit.